Published in Cancer Cell on August 01, 2004
Cancer drug resistance: an evolving paradigm. Nat Rev Cancer (2013) 6.77
Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res (2009) 4.19
ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer (2010) 3.44
CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res (2012) 2.57
Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res (2006) 2.37
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res (2013) 2.27
Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res (2006) 2.15
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
Pharmacogenomic discovery using cell-based models. Pharmacol Rev (2009) 1.96
Display technologies: application for the discovery of drug and gene delivery agents. Adv Drug Deliv Rev (2006) 1.92
Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Mol Cancer Ther (2009) 1.83
A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta (2009) 1.79
High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival. Breast Cancer Res Treat (2013) 1.78
Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2. J Biol Chem (2010) 1.74
Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res (2006) 1.64
Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch (2006) 1.58
CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics (2009) 1.58
Chemical substructures that enrich for biological activity. Bioinformatics (2008) 1.48
Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol (2008) 1.46
Drug resistance in cancer: an overview. Cancers (Basel) (2014) 1.39
APC selectively mediates response to chemotherapeutic agents in breast cancer. BMC Cancer (2015) 1.39
Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma. Pigment Cell Melanoma Res (2009) 1.38
Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol Sci (2009) 1.37
ATP-binding cassette (ABC) transporters in normal and pathological lung. Respir Res (2005) 1.37
Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res (2009) 1.35
ABCB6 is dispensable for erythropoiesis and specifies the new blood group system Langereis. Nat Genet (2012) 1.25
A dual-fluorescence high-throughput cell line system for probing multidrug resistance. Assay Drug Dev Technol (2009) 1.22
Melanoma chemotherapy leads to the selection of ABCB5-expressing cells. PLoS One (2012) 1.21
Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther (2008) 1.19
Managing drug resistance in cancer: lessons from HIV therapy. Nat Rev Cancer (2012) 1.19
Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. Proc Natl Acad Sci U S A (2006) 1.18
Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells. J Med Chem (2009) 1.17
Evaluation of biological pathways involved in chemotherapy response in breast cancer. Breast Cancer Res (2008) 1.15
Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24). Biochem Pharmacol (2007) 1.15
Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter. Mol Cancer Ther (2007) 1.13
Principal expression of two mRNA isoforms (ABCB 5alpha and ABCB 5beta ) of the ATP-binding cassette transporter gene ABCB 5 in melanoma cells and melanocytes. Pigment Cell Res (2005) 1.12
Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1). Pflugers Arch (2006) 1.11
HLA class I and II genotype of the NCI-60 cell lines. J Transl Med (2005) 1.11
Dissecting variability in responses to cancer chemotherapy through systems pharmacology. Clin Pharmacol Ther (2010) 1.11
Shifting the paradigm: the putative mitochondrial protein ABCB6 resides in the lysosomes of cells and in the plasma membrane of erythrocytes. PLoS One (2012) 1.09
RAF265 inhibits the growth of advanced human melanoma tumors. Clin Cancer Res (2012) 1.09
Flavonoid-induced glutathione depletion: potential implications for cancer treatment. Free Radic Biol Med (2006) 1.07
Role of transferrin receptor and the ABC transporters ABCB6 and ABCB7 for resistance and differentiation of tumor cells towards artesunate. PLoS One (2007) 1.06
Identification of compounds selectively killing multidrug-resistant cancer cells. Cancer Res (2009) 1.05
Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). FEBS J (2005) 1.04
Evolving concepts in cancer therapy through targeting sphingolipid metabolism. Biochim Biophys Acta (2013) 1.04
Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis. J Exp Clin Cancer Res (2009) 1.02
Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer. Curr Pharm Biotechnol (2011) 1.01
Direct and coordinate regulation of ATP-binding cassette transporter genes by Myc factors generates specific transcription signatures that significantly affect the chemoresistance phenotype of cancer cells. J Biol Chem (2010) 1.01
Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance. Chem Rev (2014) 1.00
Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines. World J Gastroenterol (2005) 1.00
A class of tricyclic compounds blocking malaria parasite oocyst development and transmission. Antimicrob Agents Chemother (2012) 0.98
The ATP-binding cassette transporter ABCB6 is induced by arsenic and protects against arsenic cytotoxicity. Toxicol Sci (2011) 0.97
Emerging Roles of SIRT1 in Cancer Drug Resistance. Genes Cancer (2013) 0.97
NCI-60 whole exome sequencing and pharmacological CellMiner analyses. PLoS One (2014) 0.93
Nicotinamide N-methyltransferase upregulation inversely correlates with lymph node metastasis in oral squamous cell carcinoma. Mol Med (2007) 0.93
NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance. PLoS One (2009) 0.93
Cancer stem cells and chemoresistance: The smartest survives the raid. Pharmacol Ther (2016) 0.93
Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60. Clin Cancer Res (2015) 0.92
ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. J Natl Cancer Inst (2014) 0.91
Using drug response data to identify molecular effectors, and molecular "omic" data to identify candidate drugs in cancer. Hum Genet (2014) 0.89
P-Glycoprotein is not present in mitochondrial membranes. Exp Cell Res (2007) 0.89
Synthesis and structure-activity evaluation of isatin-β-thiosemicarbazones with improved selective activity toward multidrug-resistant cells expressing P-glycoprotein. J Med Chem (2011) 0.89
Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations. Adv Pharmacol (2012) 0.89
Harnessing drug resistance: using ABC transporter proteins to target cancer cells. Biochem Pharmacol (2007) 0.89
Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo. Int J Cancer (2012) 0.88
Transcriptome-based identification of ABC transporters in the western tarnished plant bug Lygus hesperus. PLoS One (2014) 0.87
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner. PLoS One (2014) 0.87
RNA-mediated gene silencing of nicotinamide N-methyltransferase is associated with decreased tumorigenicity in human oral carcinoma cells. PLoS One (2013) 0.87
Improved large-scale prediction of growth inhibition patterns using the NCI60 cancer cell line panel. Bioinformatics (2015) 0.87
Influence of melanosome dynamics on melanoma drug sensitivity. J Natl Cancer Inst (2009) 0.86
Hellebrin and its aglycone form hellebrigenin display similar in vitro growth inhibitory effects in cancer cells and binding profiles to the alpha subunits of the Na+/K+-ATPase. Mol Cancer (2013) 0.86
A novel flow cytometric HTS assay reveals functional modulators of ATP binding cassette transporter ABCB6. PLoS One (2012) 0.85
Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors. Bioorg Med Chem (2012) 0.85
In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation. Mol Cancer Ther (2008) 0.85
Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen. Mol Pharmacol (2009) 0.84
Functional significance of the ATP-binding cassette transporter B6 in hepatocellular carcinoma. Mol Oncol (2011) 0.84
An In Silico Classification Model for Putative ABCC2 Substrates. Mol Inform (2012) 0.83
Tissue-specific transcript profiling for ABC transporters in the sequestering larvae of the phytophagous leaf beetle Chrysomela populi. PLoS One (2014) 0.83
Growth factor receptors and apoptosis regulators: signaling pathways, prognosis, chemosensitivity and treatment outcomes of breast cancer. Breast Cancer (Auckl) (2009) 0.82
Drug resistance is conferred on the model yeast Saccharomyces cerevisiae by expression of full-length melanoma-associated human ATP-binding cassette transporter ABCB5. Mol Pharm (2014) 0.81
Systematically characterizing and prioritizing chemosensitivity related gene based on Gene Ontology and protein interaction network. BMC Med Genomics (2012) 0.81
Comparative mitochondrial proteomic analysis of Rji cells exposed to adriamycin. Mol Med (2009) 0.81
Mining our ABCs: pharmacogenomic approach for evaluating transporter function in cancer drug resistance. Cancer Cell (2004) 0.81
The Role of Multidrug Resistance Efflux Pumps in Cancer: Revisiting a JNCI Publication Exploring Expression of the MDR1 (P-glycoprotein) Gene. J Natl Cancer Inst (2015) 0.81
Histological vis-a-vis biochemical assessment on the toxic level and antineoplastic efficacy of a synthetic drug Pt-ATP on experimental animal models. J Exp Clin Cancer Res (2008) 0.80
Synthesis of a dual functional anti-MDR tumor agent PH II-7 with elucidations of anti-tumor effects and mechanisms. PLoS One (2012) 0.80
Drug metabolism and clearance system in tumor cells of patients with multiple myeloma. Oncotarget (2015) 0.80
Characterization of cells resistant to the potent histone deacetylase inhibitor spiruchostatin B (SP-B) and effect of overexpressed p21waf1/cip1 on the SP-B resistance or susceptibility of human leukemia cells. Int J Oncol (2012) 0.80
Multidrug resistance protein 4/ ATP binding cassette transporter 4: a new potential therapeutic target for acute myeloid leukemia. Oncotarget (2014) 0.79
Targeting the chromatin remodeling enzyme BRG1 increases the efficacy of chemotherapy drugs in breast cancer cells. Oncotarget (2016) 0.79
Non-coding polymorphisms in nucleotide binding domain 1 in ABCC1 gene associate with transcript level and survival of patients with breast cancer. PLoS One (2014) 0.79
Transcriptomic insights on the ABC transporter gene family in the salmon louse Caligus rogercresseyi. Parasit Vectors (2015) 0.79
Isolation of melanoma cell subpopulations using negative selection. Methods Mol Biol (2014) 0.79
The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy. Acta Pharm Sin B (2014) 0.79
Abcc10 status affects mammary tumour growth, metastasis, and docetaxel treatment response. Br J Cancer (2014) 0.78
Design of novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties. J Cell Mol Med (2010) 0.78
Overcoming the challenges in the effective delivery of chemotherapies to CNS solid tumors. Ther Deliv (2010) 0.78
Drug Transporters and Na+/H+ Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 Proteins. Pharmacol Rev (2015) 0.78
Structure of a human multidrug transporter in an inward-facing conformation. J Struct Biol (2010) 0.78
GoMiner: a resource for biological interpretation of genomic and proteomic data. Genome Biol (2003) 22.63
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science (2006) 15.18
High-Throughput GoMiner, an 'industrial-strength' integrative gene ontology tool for interpretation of multiple-microarray experiments, with application to studies of Common Variable Immune Deficiency (CVID). BMC Bioinformatics (2005) 14.02
The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Targeting multidrug resistance in cancer. Nat Rev Drug Discov (2006) 10.55
Spatio-temporal transcriptome of the human brain. Nature (2011) 9.19
MatchMiner: a tool for batch navigation among gene and gene product identifiers. Genome Biol (2003) 8.66
Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature (2010) 8.48
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Nova regulates brain-specific splicing to shape the synapse. Nat Genet (2005) 6.58
Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer (2005) 6.46
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther (2006) 4.09
Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther (2007) 3.84
A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A (2007) 3.78
Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A (2003) 3.66
P-glycoprotein: from genomics to mechanism. Oncogene (2003) 3.66
Mistaken identifiers: gene name errors can be introduced inadvertently when using Excel in bioinformatics. BMC Bioinformatics (2004) 3.65
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping. Cancer Res (2003) 3.52
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res (2003) 3.42
MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther (2008) 3.06
MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res (2009) 3.03
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
AffyProbeMiner: a web resource for computing or retrieving accurately redefined Affymetrix probe sets. Bioinformatics (2007) 2.93
Molecular interaction maps of bioregulatory networks: a general rubric for systems biology. Mol Biol Cell (2005) 2.82
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov (2012) 2.68
Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther (2006) 2.55
DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther (2009) 2.53
MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther (2007) 2.53
Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells. Genome Biol (2003) 2.52
Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov (2013) 2.49
Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev (2012) 2.31
The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol (2008) 2.26
Mechanisms of multidrug resistance in cancer. Methods Mol Biol (2010) 2.25
The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms. Cancer Res (2008) 2.19
A stromal gene signature associated with inflammatory breast cancer. Int J Cancer (2008) 2.18
Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res (2004) 2.10
Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Res (2008) 2.01
mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. Mol Cancer Ther (2010) 2.00
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res (2007) 1.91
Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst (2010) 1.89
The organic solute transporter alpha-beta, Ostalpha-Ostbeta, is essential for intestinal bile acid transport and homeostasis. Proc Natl Acad Sci U S A (2008) 1.83
Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Mol Cancer Ther (2009) 1.83
Synonymous mutations and ribosome stalling can lead to altered folding pathways and distinct minima. J Mol Biol (2008) 1.80
A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta (2009) 1.79
An integrative genomic and epigenomic approach for the study of transcriptional regulation. PLoS One (2008) 1.76
Differences in the tumor microenvironment between African-American and European-American breast cancer patients. PLoS One (2009) 1.72
VirusSeq: software to identify viruses and their integration sites using next-generation sequencing of human cancer tissue. Bioinformatics (2012) 1.71
Drug discovery: Cell lines battle cancer. Nature (2012) 1.70
Landscape of DNA virus associations across human malignant cancers: analysis of 3,775 cases using RNA-Seq. J Virol (2013) 1.68
Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res (2006) 1.64
An analytical pipeline for genomic representations used for cytosine methylation studies. Bioinformatics (2008) 1.64
Role of type II pneumocyte senescence in radiation-induced lung fibrosis. J Natl Cancer Inst (2013) 1.64
TCPA: a resource for cancer functional proteomics data. Nat Methods (2013) 1.64
Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res (2003) 1.62
Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther (2010) 1.62
MicroRNA expression profiling in the prefrontal cortex of individuals affected with schizophrenia and bipolar disorders. Schizophr Res (2010) 1.61
Silent (synonymous) SNPs: should we care about them? Methods Mol Biol (2009) 1.61
UPLC-ESI-TOFMS-based metabolomics and gene expression dynamics inspector self-organizing metabolomic maps as tools for understanding the cellular response to ionizing radiation. Anal Chem (2008) 1.61
CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics (2009) 1.58
A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. Genes Dev (2013) 1.55
The clinical relevance of cancer cell lines. J Natl Cancer Inst (2013) 1.54
Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist Updat (2012) 1.53
Quality assessment of microarrays: visualization of spatial artifacts and quantitation of regional biases. BMC Bioinformatics (2005) 1.52
Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. Cancer Res (2007) 1.51
Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res (2003) 1.51
VennMaster: area-proportional Euler diagrams for functional GO analysis of microarrays. BMC Bioinformatics (2008) 1.49
Genomic signatures of cancer: basis for individualized risk assessment, selective staging and therapy. J Surg Oncol (2011) 1.48
Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. Cancer Res (2003) 1.48